We use cookies for a better user experience. Read our Privacy Policy
I AgreeEsophageal atresia is a condition characterized by an absence of part of the esophagus. The esophagus, also known as the 'food tube' is the conduit of food from the mouth to the stomach. It shares space with the trachea in the neck, which is the 'air tube'. Cases of esophageal atresia often coexist with tracheal atresia and tracheoesophageal fistulas, where the food and air tubes open into each other. The condition occurs in about 1 per 2,500 births globally, and is often treated by multiple surgical procedures to complete the length of the esophagus that is absent.
A rising awareness about this disease coupled with a robust infrastructure for appropriate diagnosis and treatment of diseases has led to a rise in detection and treatment of this condition. This trend is expected to continue into the future. As per Transparency Market Research, the global esophageal atresia treatment market is expected to witness growth from 2020 to 2030, owing to a number of varied trends and drivers. The robust compound annual growth rate will also lead market players towards lucrative avenues over this period. Additionally, increase in market worth would be noted.
The Global esophageal atresia treatment market is witnessing some notable developments in its landscape as proactive players take active measure towards bringing to fore effective procedures and products. It is being noted in the market landscape that players are focusing upon improvement in technology, research and development (R&D), and new and notable devices.
One such significant development in this market has been from Cook Medical, which has developed a non surgical procedure for correction of this condition. The Flourish device developed and granted FDA approval in 2018 is expected to be used increasingly in the future. This is set to spur market in a major way.
North America and Europe are currently global leaders in this market. The presence of a robust healthcare infrastructure with appropriate diagnostic and treatment facilities make the management of congenital conditions like esophageal atresia feasible and successful. Moreover, high disposable income and favorable reimbursement policies are also pushing these regional markets for esophageal atresia treatment over the forecast period.
The Asia Pacific region (APAC) is expected to register the fastest growth in this market. An increase in health consciousness supplemented by a better healthcare penetration, even to the grassroots levels and even in remote locations in this region is set to help this market grow steadily in the future.
N/A